Get started
Author

Wendela A. Kappers

Observed names: W. A. Kappers, Wendela A Kappers
ORCID: 0000-0002-8663-9731
Observed ORCID: 0000-0002-8663-9731
OpenAlex ID: A5035984434
Diazinon Is Activated by CYP2C19 in Human Liver
2001 · Wendela A. Kappers, Robert J. Edwards, et al. · Toxicology and Applied Pharmacology · 114
Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats
2015 · Inga Bjørnsdottir, Ola Sternebring, et al. · European Journal of Pharmaceutical Sciences · 32
PDF
Comparison of three different in vitro mutation assays used for the investigation of cytochrome P450-mediated mutagenicity of nitro-polycyclic aromatic hydrocarbons
2000 · Wendela A Kappers, François M.M van Och, et al. · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · 27
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
2023 · Mary J van Helden, Seline A Zwarthoff, et al. · Journal for ImmunoTherapy of Cancer · 25
PDF
Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat
2017 · Caroline E. Rasmussen, Jette Nowak, et al. · Journal of Toxicology · 17
PDF
Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al. · Molecular Cancer Therapeutics · 13
PDF
Inhibition of tolbutamide 4-methylhydroxylation by a series of non-steroidal anti-inflammatory drugs in V79-NH cells expressing human cytochrome P4502C10
1996 · W. A. Kappers, E. M. De Groene, et al. · Xenobiotica · 8
Abstract 6921: Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2026 · Mary J. van Helden, Genny Filliciotto, et al. · Cancer Research · 1
954 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2025 · Mary JVan Helden, Genny Filiciotto, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Data from Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate
2024 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
1160 Phosphonate-antibody-drug conjugates: a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing
2023 · Mary J van Helden, Ronald C Elgersma, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Supplementary Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Data from Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate
2023 · Patrick G. Groothuis, Daniëlle C.H. Jacobs, et al.
Works count: 17
Citation count: 237
H-index: 7
I10-index: 6
Year
Topic
Type